Taspoglutide: Completed Phase III enrollment

Roche completed enrollment of 990 patients with Type II diabetes mellitus inadequately controlled with metformin plus sulphonylurea in the open-label,

Read the full 208 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE